Background: Clinicians frequently use hydrocortisone (HC) to treat vasopressor-resistant hypotension even before establishing its cause.
Introduction
Systemic hypotension is a common complication of sick preterm infants and may be associated with poor outcomes, including intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), other neurodevelopmental morbidities and mortality. [1] [2] [3] [4] It is generally accepted that the most appropriate initial treatment strategy for systemic hypotension requires identification of the primary etiologic factor or combination of factors leading to the clinical presentation of hypotension. While the combination of hydrocortisone (HC) and vasopressors has now increasingly become the treatment of choice in preterm neonates with refractory hypotension, 5, 6 it is not often realized that early clinically silent significant ductal shunting can lead to sustained hypotension unresponsive to vasopressor treatment. 7, 8 Meta-analysis of surfactant trials has found an increased risk that a clinically symptomatic patent ductus arteriosus (PDA) with earlier clinical presentation of left-to-right shunting will develop after surfactant therapy; this risk is highest among infants treated prophylactically with surfactant, mediated via its effects on pulmonary vascular resistance. 9 The PDA-related hypotension, often characterized by low diastolic and mean arterial blood pressure (MABP) values, is sustained if closure of the ductus is not achieved. With more emphasis on the use of prophylactic surfactant therapy these days, more very low birth weight (VLBW) infants are developing an early hemodynamically significant PDA. As PDA-related hypotension may be refractory to vasopressor treatment, more preterm infants are probably treated for refractory hypotension with HC before it is established whether hypotension is symptomatic of another problem, notably PDA. If a hemodynamically significant PDA is the cause of sustained and refractory hypotension, neither of these treatments is appropriate.
Hypothesis
We hypothesize that refractory hypotension in preterm infants outside the transitional period might be the early sign of clinically silent significant ductal shunting.
Objective
The purpose of this study is to identify the etiologic factors leading to the clinical presentation of refractory hypotension in preterm infants and to assess if PDA is associated with sustained refractory hypotension during the first week of life.
Methods
The computerized medical records and nursing flowsheets of all preterm infants p30 weeks gestational age (GA) consecutively admitted to the Holden neonatal intensive care unit (NICU) at the University of Michigan from January 2001 through December 2005 were reviewed to identify the infants with an escalating need for vasopressors to maintain the MABP at or above the desired level. Only preterm infants born p30 weeks of gestation were reviewed, as spontaneous closure of PDA is more frequent in larger and more mature infants, particularly so in infants >30 weeks and born to mothers who received antenatal steroid therapy. 10, 11 Our clinical practice is to maintain the MABP at or above a level equal to the GA in completed weeks. 12 According to divisional guidelines, a serum cortisol level is obtained and a trial of 'stress dose' HC administration (45 mg/m 2 /day divided q6h for 8 doses) is considered if the MABP remains at or below this level despite volume administration and high-dose pressor/inotrope support, arbitrarily defined as the combined use of dopamine and dobutamine at doses 20 mg/kg/min each and/or epinephrine. Hypotension unresponsive to volume administration and high-dose pressor/inotrope support prompting use of HC was deemed to be refractory hypotension.
In our NICU, blood pressures including the systolic, mean and diastolic values, the nature of vasopressors and use of volume expanders, if any, are recorded on the nursing flow sheet every 15 to 60 min depending on the instability of the cardiovascular status of the patient. Blood pressure data are obtained from an umbilical or peripheral arterial catheter connected to a pressure transducer and displayed on a monitor and/or from automated oscillometric blood pressure measurements.
Data on the presence of selected parameters at the start of HC therapy were reviewed to delineate the etiologic factors associated with development of refractory hypotension during the first week of life. The parameters included the presence or absence of blood culture proven sepsis, necrotizing enterocolitis (NEC), IVH, severe IVH (grade 3 or 4), severe and persistent hypoglycemia, hypocalcemia or hypermagnesemia despite medical management, severe metabolic acidosis from inborn errors of metabolism, uncontrollable hyperkalemia despite treatment (calcium, insulin-glucose infusion and albuterol), dysrhythmia (e.g., SVT or atrial flutter), pulmonary air leak, use of highfrequency ventilation, presence of clinically diagnosed and/or echocardiographically proven PDA at or subsequent to the start of HC treatment and the details of PDA treatment including use of indomethacin and/or surgical ligation. Presence or absence of maternal chorioamnionitis, placental abruption, pre-eclampsia, antenatal steroid treatment, maternal magnesium sulfate therapy, the birth weight and GA of the infant, gender, Apgar scores, mode of delivery, multiple birth, details of delivery room resuscitation and surfactant therapy were also reviewed.
Patients were excluded from evaluation if they had (1) refractory hypotension on the first postnatal day, which is usually because of delayed postnatal transition; (2) major or lethal congenital or chromosomal abnormalities; (3) congenital heart defects (excluding PDA) and (4) early death before postnatal day 2.
In our NICU during this time, VLBW infants who are intubated and receiving positive pressure ventilation for respiratory distress syndrome are given a standard course of surfactant treatment. PDA was treated with indomethacin only when it was thought to be compromising the infant's overall clinical and ventilatory status and prophylactic indomethacin was not used. Serum glucose, serum magnesium and ionized calcium are followed closely. Adjustments are made in the glucose infusion rate to prevent significant hypoglycemia and calcium boluses are used to maintain ionized calcium >1.0 mmol/L. An echocardiogram for PDA is performed only when clinically indicated and specifically to rule out ductal-dependent cardiac lesion before indomethacin therapy is instituted.
Statistical analyses
SPSS was used for data analyses. For univariate analysis, t-tests and w 2 test were employed to determine which of the maternal and neonatal factors were significantly associated with the development of vasopressor unresponsive hypotension. Stepwise logistic multivariate regression analysis was used to test if PDA is independently associated with refractory hypotension after controlling for the effects of other potential confounding variables seen with univariate analysis.
Results
The study population consisted of 290 of 322 preterm infants; two infants with refractory hypotension treated with HC on the first postnatal day, 11 infants with complex congenital heart defects (with or without chromosomal abnormalities) and 19 infants with early deaths were excluded from data analysis.
Eighty-nine (30.7%) infants had refractory hypotension that was treated with HC between postnatal days 2 and 7. Demographic and clinical variables for the group with and without refractory hypotension are shown in Tables 1 and 2 . Infants with lower birth weights and GAs were significantly more likely (P<0.001 for both) to have refractory hypotension. Fewer infants born to mothers who received antenatal steroid developed refractory hypotension (P ¼ 0.012). Multiple gestation, mode of delivery, maternal preeclampsia, preterm prolong rupture of membrane, antepartum hemorrhage, chorioamnionitis, antenatal magnesium sulfate, and antibiotic therapy did not significantly affect the development of refractory hypotension (Table 2) . Infants with refractory hypotension were more likely to have a lower Apgar score at 5 min (P ¼ 0.001), received cardiac compressions at birth (P ¼ 0.029), been treated with surfactant for respiratory distress syndrome (RDS) (P ¼ 0.004) and received indomethacin for a symptomatic PDA (P<0.001). To identify the commonly cited etiologic factors leading to the clinical presentation of refractory hypotension, a univariate analysis revealed that the use of high-frequency oscillatory ventilation and the presence of air leaks, PDA, blood culture proven sepsis, significant hyperkalemia and both IVH and severe IVH were significantly associated with the development of refractory hypotension. Severe metabolic acidosis from ornithine transcarbamylase deficiency (two infants) and supraventricular tachycardia (SVT) (one infant) causing refractory hypotension were not included as possible etiologic factors in the univariate model. None of the study infants had persistent symptomatic hypoglycemia, hypocalcemia or hypermagnesemia attributable to the causation of refractory hypotension.
To determine the variables predicting refractory hypotension in the study population, multivariate analysis (after removal of the nonsignificant covariates on univariate model), confirmed the independent association of only PDA (odds ratio (OR) 7.7, 95% confidence interval (CI) 3.3-17.7, P ¼ 0.000), severe IVH Abbreviations: CI, confidence interval; OR, odds ratio; PIH, pregnancy-induced hypertension; PPROM, preterm prolong rupture of membrane; P/V, per vagina.
Refractory hypotension is indicative of early ductal shunting S Sarkar et al (OR 2.6, 95% CI 1.1-6.4, P ¼ 0.03) and GA (OR 0.7, 95% CI 0.6-0.8, P ¼ 0.001) with the development of refractory hypotension (Table 3) . Serum cortisol concentrations obtained before starting HC were available in 74 of the 89 infants with refractory hypotension and ranged from 1.1 to 38 mcg/dl (mean 8.08±s.d. 7.6; median 5.5 mcg/dl).
Fifty-three infants with refractory hypotension subsequently received indomethacin treatment to close the PDA. The development of hypotension with escalating need for vasopressors and ultimately the start of HC in these 53 infants temporally preceded the diagnosis of symptomatic PDA. The age of these infants at the start of HC for refractory hypotension was 2.6±s.d. 1.3 (median 2 days) and for indomethacin therapy for symptomatic PDA was 3.8±s.d. 2 (median 3 days) postnatal days.
Adverse outcomes (IVH, severe IVH, PVL and/or posthemorrhagic ventricular dilatation requiring reservoir or shunt placement, NEC, NEC surgery, surgical ligation of PDA, laser surgery for advanced retinopathy of prematurity, need for home oxygen at discharge or oxygen dependency at transfer and mortality) were more common in the infants who had refractory hypotension during the first week of life (Table 4) .
Intestinal perforation for which surgical intervention occurred appeared to be associated with both HC and indomethacin treatment (P ¼ 0.001 and 0.025, respectively) in the study infants and the effect of HC on the perforation rate appeared to be greater if indomethacin was also administered compared with indomethacin treatment alone ( Table 5 ).
Discussion
The causes of hypotension in preterm infants during first week of life are diverse and multifactorial. The underlying causes of hypotension and/or decreased systemic blood flow in preterm VLBW infants during the immediate postnatal period are usually delayed postnatal transition, abnormal peripheral vasoregulation and myocardial dysfunction from maternal chorioamnionitis or perinatal depression. 13 From the second postnatal day, hypotension is commonly related to a hemodynamically significant PDA, relative adrenal insufficiency and vasopressor/inotrope resistance, high mean airway pressure during mechanical ventilation; pulmonary air leaks, cardiac arrythmias, electrolyte disturbances (notably hyperkalemia, hypermagnesemia, and persistent hypocalcemia), myocardial depression from persistent hypoglycemia, severe metabolic acidosis as seen in inborn errors of metabolism and/or specific systemic inflammatory response syndromes, such as seen in cases with sepsis and/or NEC. Abbreviations: CI, confidence interval; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; OR, odds ratio; PDA, patent ductus arteriosus; PHVD, posthemorrhagic ventricular dilatation; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity. a Data for this outcome exclude infants who died before scheduled head ultrasound at 3-4 weeks of age. b All cases of NEC occurred after the first week of life.
c Data for this outcome include only the infants who were alive until at least one eye examination for ROP before discharge to home or transfer to another hospital or death.
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Absolute hypovolemia is a much less frequent primary cause of neonatal hypotension, especially in the immediate postnatal period. 13 In the present study, we have shown that hypotension unresponsive to vasopressors was significantly associated with subsequent diagnosis of a hemodynamically 'significant' PDA warranting medical management (indomethacin, fluid restriction, etc) and/or surgical ligation. 'Significance' is somewhat subjective, which not only varies among neonatologists, but also among patients. Some infants with a large shunt on echocardiogram seem to do fine clinically, while others do poorly, with early signs of low cardiac output, respiratory failure and subsequent development of IVH and/or PVL. Although the presence of classical clinical signs often accompanies a large PDA with the left-to-right shunting, the absence of clinical signs does not exclude the presence of a PDA with a large shunt, especially during the first few days of life.
14 Such infants can exhibit cardiovascular collapse from a large shunt, without having detectable clinical signs of ductal shunting, referred to as a 'silent dangerous ductus'. 14 We believe that refractory hypotension in our study infants represents early clinical manifestation of such silent significant ductal shunting.
Several lines of evidence suggest that the association between PDA and refractory hypotension might have been causal in origin. First, hypotension with escalating need for vasopressors in our study population temporally preceded the diagnosis of PDA. Second, the hypothesis that PDA may cause vasopressor-resistant hypotension is physiologically plausible. As myocardial function is initially preserved, administration of dobutamine in PDA-related hypotension often does not improve the hypotension. The use of an inotrope, such as dopamine, may further increase pulmonary blood flow and thus left-to-right shunting across ductus, since dopamine increases systemic vascular resistance more than pulmonary vascular resistance. 15 Third, that PDA is implicated in the pathogenesis of hypotension is supported by studies which examined the effect of a hemodynamically significant PDA on systemic blood pressure by Doppler echocardiography during the first week of life and also by the observation of increased blood pressure following closure of a hemodynamically significant PDA with indomethacin. 7, 8 Fourthly, one recent study has demonstrated that administration of prophylactic indomethacin significantly decreases the occurrence of hypotension. 4 In that study, it was interesting to note that the two sites with the highest rates of hypotension were the sites where prophylactic indomethacin was rarely used.
We also observed that the least mature infants in our study were the ones most likely to have refractory hypotension, which is consistent with previous reports by Zubrow et al. 16 Infants with refractory hypotension are more likely to have severe IVH, 3, 4 as seen in our study infants, and this may be because of the impairment of vascular autoregulation, which leaves cerebral blood flow at the mercy of perfusion pressure. 17 The retrospective nature of our study precludes us, however, from determining whether hypotension occurred first and led to severe IVH, or IVH occurred first, leading to refractory hypotension. Hyperkalemia was also noted to be significantly associated with development of refractory hypotension, but the small number of the infants with hyperkalemia and a very wide confidence interval make it difficult to interpret this finding.
The role of relative adrenal insufficiency and vasopressor/ inotrope resistance could not be evaluated in our study as the serum cortisol concentrations were not obtained in preterm infants without refractory hypotension. In infants with refractory hypotension, the serum cortisol concentrations varied widely, although the mean concentration seems to be low. It is important to note that HC improves blood pressure at the expense of systemic perfusion by increasing the peripheral vasoconstrictive effect of vasopressors. 13 HC actually may worsen left-to-right ductal shunting, at least in theory, if the closure of PDA is not achieved before the drug is started in preterm infants with refractory hypotension even in the presence of relative adrenal insufficiency.
Our study also highlights the observation made by Watterberg et al. 18 that once infants are started on HC for refractory hypotension, subsequent treatment of the PDA with indomethacin is risky because of increased risk of intestinal perforations, especially when it is used concurrently with indomethacin.
In summary, in this large retrospective observational study, refractory hypotension outside the transitional period in preterm VLBW infants might have been the early presenting sign of significant but clinically silent ductal shunting. Although the retrospective study design limits the interpretation of these data, the strength of this investigation lies in the large number of VLBW infants with or without PDA who were exposed to HC for treatment of refractory hypotension. Despite limited information on safety and efficacy, and despite the lack of appropriately designed prospective clinical trials, clinicians are still frequently using HC to treat 
